Hodgkin Lymphoma Video Series - Oncology Nurse Advisor

Hodgkin Lymphoma Video Series

Chapter 2

Autologous Stem Cell Transplant for Patients with Hodgkin Lymphoma

Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss the approximate 20% of patients with relapsed/refractory Hodgkin lymphoma and factors and risks related to autologous stem cell transplant, including psychosocial factors.

Chapter 3

Targeted Therapies for Hodgkin Lymphoma

Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss current research focused on the treatment of Hodgkin lymphoma with targeted therapies.

Chapter 4

Treating Patients With Hodgkin Lymphoma with Targeted Therapies

Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss issues that affect patients who are treated with targeted therapies.

Chapter 5

Efficacy and Safety of Targeted Therapies for Hodgkin Lymphoma

Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss the efficacy and safety of targeted therapies for the treatment of Hodgkin lymphoma, specifically the results from the AETHERA study.

Chapter 6

Managing Adverse Events in Patients Being Treated with Brentuximab Vedotin

Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss strategies to manage various adverse events that occur in patients with Hodgkin lymphoma being treated with brentuximab vedotin.

Chapter 7

Research in New Agents for Relapsed/Refractory Hodgkin Lymphoma

Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss current research related to the use of nivolumab and pembrolizumab for patients with relapsed/refractory Hodgkin lymphoma.

Chapter 8

Overview of Anaplastic Large Cell Lymphoma

Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss the first-line treatment approach and prognostic factors used in anaplastic large cell lymphoma.

Chapter 9

Treatment Options in Relapsed/Refractory Anaplastic Large Cell Lymphoma

Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss the options in terms of treatment for patients with relapsed/refractory anaplastic large cell lymphoma and novel agents in this patient population.

Chapter 10

Managing Adverse Events in Relapsed/Refractory Anaplastic Large Cell Lymphoma

Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss the most common adverse events in patients being treated with novel agents for relapsed/refractory anaplastic large cell lymphoma.